I set out to write a quick article on Biogen, but one thing led to another, and it expanded into a relatively detailed analysis. I own Biogen, and while there are some negatives in the picture like declining interferon sales, on the whole it looks very positive for the next few years.
The full article:
Biogen (BIIB) Keys to Value in 2017 and Beyond
Keep diversified!
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment